-
The seventh batch of national procurement was opened: 58 drugs, nearly half of which were injections
Time of Update: 2022-03-03
According to industry analysis, it is expected that the competition in this centralized procurement will be fierce, because the number of over-reviewed companies for some products has reached more than 10, such as omeprazole injection, nifedipine sustained-release/controlled-release dosage forms, propofol Norfovir oral normal-release dosage form, clindamycin phosphate injection, cefixime oral normal-release dosage form, etc.
-
Kinetic evaluation from the perspective of drug discovery
Time of Update: 2022-03-03
As pharmaceutical companies focus more on optimizing target-binding affinity and selectivity, pharmacokinetics are often overlooked, although there is growing evidence that kinetic parameters may correlate more strongly with drug efficacy than affinity parameters .
-
In 2022, the size of my country's API market is expected to exceed 400 billion yuan, facing two major challenges
Time of Update: 2022-03-03
The continuous production guidance document issued by the FDA clearly encourages API and generic drug companies to use continuous reactions in the production of small-molecule pharmaceutical products to improve product quality and reduce manufacturing costs .
-
A wholly-owned subsidiary of Kexing Pharmaceuticals cooperates with Antaiwei to develop small-molecule oral drugs against the new coronavirus
Time of Update: 2022-03-03
On February 20, Kexing Pharmaceutical announced that its wholly-owned subsidiary Shenzhen Kexing signed the "SHEN26 Project Cooperation Agreement" (hereinafter referred to as the "Cooperation Agreement") with Antaiwei on February 18.
SHEN26 is an antiviral drug for the treatment of novel coronavirus and other viral infections.
-
The seventh batch of national mining competition situation prediction: four influencing factors, five competition levels
Time of Update: 2022-03-03
Most of the domestic leading pharmaceutical companies have implemented the strategy of combining imitation and innovation and competition in the industry chain, and have already deployed the first generic drugs and APIs to achieve a one-year market exclusivity period.
-
Chia Tai Tianqing grabs 1.5 billion antibacterial injections!
Time of Update: 2022-03-03
0 China Drug Evaluation Database At present, 12 companies have production approvals for Linezolid Glucose Injection, of which 6 companies have reviewed them, and 5 companies including Sichuan Meida Konkale Pharmaceutical, Hunan Kelun Pharmaceutical, and Jiangsu Zhengda Fenghai Pharmaceutical have obtained supplementary applications.
-
The second batch of catalogues of "Hong Kong and Macao Pharmaceutical Machinery" is released!
Time of Update: 2022-03-03
On February 18, according to the website of the Guangdong Provincial Drug Administration, the Guangdong Provincial Drug Administration and the Guangdong Provincial Health Commission released the second batch of the Guangdong-Hong Kong-Macao Greater Bay Area clinical urgent need to import Hong Kong and Macao medicines and medical devices catalog .
-
27 injection varieties were shortlisted for the seventh batch of national procurement, and this industry is poised for development!
Time of Update: 2022-03-03
According to the needs of the water injection production process, its production equipment includes liquid dispensing and filtration equipment, ampoule sterilization and drying equipment, ampoule washing equipment, potting equipment, sterilization leak detection equipment, lamp inspection equipment, etc.
-
Eli Lilly IL-23p19 Inhibitor Has Significant Clinical Efficacy in Phase 3 Treatment of Ulcerative Colitis
Time of Update: 2022-03-03
This is a 12-week placebo-controlled induction Phase 3 study evaluating the efficacy and safety of mirikizumab in patients with moderate-to-severe UC who have failed conventional and/or biological therapy and/or a JAK inhibitor .
-
This year, small and medium-sized chain pharmacies operate like this
Time of Update: 2022-03-03
Chain pharmacies that have already registered their stores online will inevitably increase their varieties and innovate models to further serve online and offline customers .
-
Recently, a number of domestic new drugs have ushered in new progress in the market!
Time of Update: 2022-03-02
Chengdu Baiyue will enter the anticoagulant market of over $10 billion On February 8, Chengdu Baiyu Pharmaceutical entered the administrative approval stage with a generic 4-type apixaban tablet, which is expected to become the company's second over-reviewed antithrombotic drug form medicine .
-
Since the beginning of this year, a large number of drugs have been cancelled due to their prices!
Time of Update: 2022-03-02
It is understood that the notice of Shaanxi Province on the cancellation of the eligibility of some products to be listed on the Internet was made in accordance with the "Implementation Plan for the Dynamic Adjustment of the Drug Sunshine Network of the Shaanxi Provincial Public Resource Trading Center" .
-
AstraZeneca terminates development of Phase II/III COVID-19 vaccine AZD2816
Time of Update: 2022-03-02
AZD2816 is an improved vaccine against the Beta variant, developed using the same adenoviral vector technology platform as Vaxzevria .
On June 27, 2021, AstraZeneca announced that the first subjects of the Phase II/III clinical trial of AZD2816 had completed the vaccination .
-
70 traditional Chinese medicine companies disclosed performance forecasts, and more than half were positive!
Time of Update: 2022-03-02
In addition, Zuoli Pharmaceutical expects that the net profit attributable to shareholders of listed companies in 2021 will be 170 million to 187 million yuan, a year-on-year increase of 91.
-
This company, which plans to sell 3 pharmaceutical companies for 1.3 billion yuan, received the Shenzhen Stock Exchange's restructuring inquiry letter
Time of Update: 2022-03-02
On February 16, Shenzhen Stock Exchange issued a restructuring inquiry letter to VTR . It pointed out that on January 29, VTR disclosed the "Report on the Sale of Major Assets and Related Party Tran
-
AI pharmaceutical has become a trend, attracting domestic and foreign pharmaceutical companies to compete for layout
Time of Update: 2022-03-02
On January 11 this year, after Fosun Pharma and Insilicon announced their "marriage", on February 17, the two parties announced that they had nominated the preclinical candidate compound ISM004-1057D for the cooperation project for new tumor immunotherapy .
-
Notice of the State Food and Drug Administration on Issuing the Catalogue of Generic Drug Reference Preparations (Fifty Batch) (No. 9, 2022)
Time of Update: 2022-03-02
Notice of the State Food and Drug Administration on Issuing the Catalogue of Generic Drug Reference Preparations (Fifty Batch) (No.
Attachment: Catalogue of Generic Drug Reference Preparations (Fifty Batch) State Food and Drug Administration February 10, 2022 Relevant attachments serial number accessory name 1 Annex to the Circular No.
-
Analysis of China's innovative drug IND trends
Time of Update: 2022-03-02
Among the new drugs that will apply for IND for the first time in 2021, due to the explosion in the number of double antibodies, the popularity of PDL1, TGF-β, 4-1BB, CD47 and other target combinations has also increased rapidly, and the targets of small molecule drugs are concentrated in KRAS G12C, BTK, SHP2, TOP15 target related drugs totaled 155, accounting for 25% .
-
What are the requirements for the certification documents of pharmaceutical packaging materials?
Time of Update: 2022-03-02
In the "Key Points of Formal Review", the draft for comments made requirements for pharmaceutical packaging materials in the aspects of registration form review points and registration data review points .
-
The State Food and Drug Administration approved the registration of 208 medical device products in January
Time of Update: 2022-03-02
On February 18, the State Food and Drug Administration announced that a total of 208 registered medical device products will be approved in January 2022 .
